profit from every ₹100 of sales.
₹0₹100
Apollo Hospitals Enterprise
₹8,526.00+0.13% today
+23.2% in 1 year
1-year low ₹6,793.501-year high ₹9,069.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹63.14 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Apollo Hospitals Enterprise sold, what it kept, and what it did with the cash.
Sales went from ₹164 billion in 2023 to ₹252 billion in 2026, with ₹19.4 billion of profit last year.
SalesProfit
Apollo Hospitals Enterprise handed back 32% of the cash it generated last year.
₹2.9B
Free cash flow 2026₹8.9B
Bought back its own shares–
Paid as dividends₹2.9B
Cash vs. debt₹8.1B vs. ₹84.9B
Apollo Hospitals Enterprise vs. similar companies
Apollo Hospitals Enterprise grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Apollo Hospitals Enterprise | 63.1× · Very expensive | ||
 HCA Healthcare | 15.4× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.9× · Fair price | ||
 IHH Healthcare Berhad | 34.3× · Expensive | ||
 Rede D'Or São Luiz | 16.2× · Fair price |
AI analysis
An AI analyst reads Apollo Hospitals Enterprise's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 164,448 | 188,623 | 217,940 | 252,285 | |
| 78,705 | 90,568 | 104,840 | 121,529 | |
| 14,492 | 17,073 | 22,643 | 28,932 | |
| 20,728 | 24,776 | 32,551 | 39,866 | |
| 8,191 | 8,986 | 14,459 | 19,417 | |
| 56.97 | 62.50 | 100.56 | 135.04 | |
| 47.9% | 48.0% | 48.1% | 48.2% | |
| 8.8% | 9.1% | 10.4% | 11.5% | |
| 5.0% | 4.8% | 6.6% | 7.7% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 144,278 | 167,531 | 206,574 | 221,969 |
| Cash | 4,334 | 5,055 | 5,781 | 8,113 |
| Total debt | 43,324 | 53,326 | 54,192 | 84,929 |
| Total liabilities | 78,965 | 94,326 | 120,045 | 122,224 |
| 61,974 | 69,354 | 82,123 | 94,801 | |
| 144 | 144 | 144 | 144 | |
| 10.4% | 10.9% | 13.7% | 13.0% | |
| 13.2% | 13.0% | 17.6% | 20.5% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 13,769 | 19,202 | 21,364 | 28,557 | |
| 11,285 | 11,368 | 17,127 | 19,620 | |
| 2,484 | 7,834 | 4,237 | 8,937 | |
| Dividends paid | 2,552 | 2,157 | 2,732 | 2,876 |
| – | – | – | – | |
| 760 | 875 | 1,127 | 1,589 |
Valuation
- 63.1×
- –
- 1.89
- 12.4×
- 4.9×
- 137.2×
- 32.7×
- 0.7%
- 1.6%
- 0.2%
Profitability
- 48.2%
- 11.5%
- 7.7%
- –
- 13.0%
- 12.0%
- –
- –
- –
- –
Growth
- +15.3%
- +33.3%
- –
- –
- +0.0%
Financial health
- 1.9×
- 0.90
- –
- 6.9×
- 1.06
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 19%of 946
Top 44%of 872
Bottom 16%of 565
Top 37%of 867
Bottom 46%of 986
0.2%of the share price, paid each year
On $1,000 invested$2a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
14.8% of its profit
Room to growStretchedMore than it earns: 32.2%
News
Nvidia and Apollo in talks to repurpose Brightspeed telecom buildings for AI: reportSeeking Alpha · Nov 6, 2026UDR signals 80-100 bps 2027 same-store revenue earn-in as $2B Apollo JV closesSeeking Alpha · Nov 3, 2026Apollo launches European credit platform with €10B-plus lending capacitySeeking Alpha · Nov 2, 2026Is AI Overhyped? Apollo Economist Sees "Zero Financial Payoff" Beyond Tech CompaniesYahoo Finance · Oct 28, 2026Apollo Global near deal to buy 10% stake in Mubadala Capital - CNBCSeeking Alpha · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
30No pass
Philip Fisher
52No pass
Peter Lynch
67Pass
Joel Greenblatt
9No pass
Charlie Munger
29No pass
Terry Smith
23No pass
Questions about Apollo Hospitals Enterprise
Is Apollo Hospitals Enterprise a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Apollo Hospitals Enterprise AI analysis
What does Apollo Hospitals Enterprise do?
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. It is in Medical Care Facilities, based in Chennai, India.
Does Apollo Hospitals Enterprise pay a dividend?
Yes. At today's price the dividend is 0.2% a year, about 15% of its yearly profit. In 2026 it paid out ₹2.88 billion in dividends.
Is Apollo Hospitals Enterprise stock halal?
Yes. Apollo Hospitals Enterprise passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Apollo Hospitals Enterprise stock done over the past year?
Up 23.2% over the past twelve months, to ₹8,526.00. It traded between ₹6,793.50 and ₹9,069.00 and is 6.0% below its high.
Who are Apollo Hospitals Enterprise's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with Apollo Hospitals Enterprise's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.